Neurological Disorders and Diseases

Disease State Hub

Commentary

Research Summaries

Guideline Update

Guideline Update

AAN, AHS Issue Updated Adult Migraine Prevention Guideline

09/21/2026

Anthony Calabro, MA

An updated evidence-based practice guideline published in Headache outlines when to initiate pharmacologic migraine prevention in adults and how to select, assess, and discontinue treatment.

09/21/2026

FDA Approval

FDA Approval

FDA Approves Zanvastro as First Treatment for Alexander Disease

09/16/2026

Anthony Calabro, MA

Clinical and pharmacokinetic evidence supported approval of zilganersen across pediatric and adult age groups, providing the first therapy designed to reduce production of the abnormal GFAP protein...

09/16/2026

FDA Approval

FDA Approval

FDA Approves Isembyld as First Spinal Muscular Atrophy Therapy Targeting Muscle Loss

09/15/2026

Anthony Calabro, MA

A 52-week trial evaluated apitegromab-mstn as an adjunct to SMN2-targeted treatment in patients with spinal muscular atrophy who could not move or walk independently, demonstrating improved motor function...

09/15/2026

AHS Conference Coverage

AHS Conference Coverage

Atogepant Reduces Blood Pressure in Participants With Migraine, Overweight or Obesity, and Baseline Hypertension

08/31/2026

Anthony Calabro, MA

A 1-year interim analysis of a phase 3, multicenter, open-label, 156-week extension study found overall reductions in systolic and diastolic blood pressure with atogepant 60 mg once daily in persons with...

08/31/2026

FDA Alert

FDA Alert

FDA Approves Orzeyful for Narcolepsy Type 1 in US Adults

08/28/2026

Ashton L. Stahl

Two randomized, placebo-controlled studies evaluated treatment across the full spectrum of narcolepsy type 1 symptoms in adults.

08/28/2026

October 2026

Current Issue

October 2026